SPECIAL REPORT

DEA proposes rescheduling combination hydrocodone drugs

The Drug Enforcement Administration's proposal to move hydrocodone combination products from Schedule III to Schedule II late last week could have a major impact on pharmacies.

"According to the DEA, twice as many high school seniors abuse Vicodin, an hydrocodone combination product, as those who abuse OxyContin, a Schedule II drug that is more tightly controlled."

Other Coverage

• Fearing more overdoses, groups urge FDA to rescind Zohydro approval

• Opinion: The hydrocodone question

• ASHP supports reclassifying hydrocodone products

Editorial Questions? Contact the Editorial Team. Click Here.
Sales, Reprints, Classified questions? Contact the Sales Team. Click Here.